Cargando…

Individualized treatment with infliximab therapy in children with Crohn’s disease support shorter time intervals between infusions

OBJECTIVES: To study the effect of an individualized treatment approach with regard to dosage intervals between infliximab infusions on the clinical outcome of pediatric Crohn’s disease (CD). PATIENTS AND METHODS: A retrospective analysis of medical records of all pediatric patients with CD who had...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sommar, M., Eksborg, S., Hildebrand, H., Grahnquist, L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2012
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980724/ https://www.ncbi.nlm.nih.gov/pubmed/27536423 http://dx.doi.org/10.3109/21556660.2012.655815

Ejemplares similares

Loss of Response to Long-Term Infliximab Therapy in Children with Crohn’s Disease
por: Gouldthorpe, Oliver, et al.
Publicado: (2013)

Metastatic Crohn’s disease despite infliximab therapy
por: Campos, Sara, et al.
Publicado: (2017)

Case Report: Infusion-Related Reactions to Intravenous Infliximab and Subcutaneous Ustekinumab in Pediatric Crohn's Disease
por: Kakiuchi, Toshihiko, et al.
Publicado: (2021)

Infliximab in the treatment of Crohn’s disease
por: Poggioli, Gilberto, et al.
Publicado: (2007)

Infliximab therapy in pediatric Crohn’s disease: a review
por: Parashette, Kalyan Ray, et al.
Publicado: (2010)

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
por: Vande Casteele, Niels, et al.
Publicado: (2015)

Optimized timing of using infliximab in perianal fistulizing Crohn's disease
por: Sun, Xue-Liang, et al.
Publicado: (2020)

Acid reducing agents to neonates – lack of evidence and guidelines
por: Paulsson, Stina, et al.
Publicado: (2012)

Response to Infliximab in Crohn's Disease: Genetic Analysis Supporting Expression Profile
por: Medrano, Luz María, et al.
Publicado: (2015)

Infusion reaction to infliximab biosimilar after transitioning from infliximab
por: Kashlan, Reem, et al.
Publicado: (2020)

Decreasing Door-to-Door Times for Infliximab Infusions in a Children's Hospital Observation Unit
por: Sandberg, Kelly C., et al.
Publicado: (2019)

Proactive measurement of infliximab drug levels in children with Crohn’s disease
por: Holland, Kathleen, et al.
Publicado: (2022)

Early intestinal obstruction after infliximab therapy in Crohn’s disease
por: Chiba, Mitsuro, et al.
Publicado: (2019)

Brain Abscesses in Crohn’s Disease as a Complication of Infliximab Therapy
por: Mansour, Mahmoud M, et al.
Publicado: (2021)

Infliximab to treat Crohn’s disease: an update
por: Cottone, M, et al.
Publicado: (2011)

Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn's Disease
por: Gomes, Luis Eduardo Miani, et al.
Publicado: (2019)

B-Cell Dysregulation in Crohn's Disease Is Partially Restored with Infliximab Therapy
por: Timmermans, Wilhelmina M. C., et al.
Publicado: (2016)

Intestinal fibrosis is associated with lack of response to Infliximab therapy in Crohn's disease
por: de Bruyn, Jessica R., et al.
Publicado: (2018)

Large Bowel Progressive Stricture after Infliximab Therapy for Crohn's Disease
por: Matsueda, Katsunori, et al.
Publicado: (2018)

Chronic Inflammatory Demyelinating Polyneuropathy in Patients With Crohn’s Disease on Infliximab Therapy
por: Almuntashri, Fahad, et al.
Publicado: (2021)

Henoch-Schönlein purpura associated with infliximab therapy for pediatric Crohn’s disease
por: Li, Xiaolu, et al.
Publicado: (2022)

Profile of infliximab in the treatment of pediatric Crohn’s disease
por: Kierkus, Jaroslaw, et al.
Publicado: (2015)

Myelolipoma After Infliximab Treatment for Crohn's Disease
por: Cesa, Kevin, et al.
Publicado: (2022)

Infliximab for medical induction of remission in Crohn's disease
por: Gordon, Morris, et al.
Publicado: (2023)

Infliximab-Related Infusion Reactions: Systematic Review
por: Lichtenstein, Lev, et al.
Publicado: (2015)

Changes in the Intestinal Microbiota Are Seen Following Treatment with Infliximab in Children with Crohn’s Disease
por: Kowalska-Duplaga, Kinga, et al.
Publicado: (2020)

Multiple liver abscesses in Crohn’s disease in infliximab therapy, successfully treated with antibiotic therapy
por: Otheo, Enrique, et al.
Publicado: (2019)

Seizure During Infliximab Infusion in a Child With Crohn’s Disease: An Illustration of a Neurologic Adverse Event Associated With Drug Antibodies
por: Joseph, Shelly, et al.
Publicado: (2021)

Influence of previous corticosteroid treatment on the efficacy and safety of infliximab therapy in Crohn disease
por: Liu, Ailing, et al.
Publicado: (2019)

Exclusive Enteral Nutrition versus Infliximab in Inducing Therapy of Pediatric Crohn's Disease
por: Luo, Youyou, et al.
Publicado: (2017)

Factors Affecting Surgical Treatment With Infliximab Therapy in Perianal Fistula With Crohn Disease
por: Lee, Jong Lyul
Publicado: (2019)

Microbial and metabolic features associated with outcome of infliximab therapy in pediatric Crohn’s disease
por: Wang, Yizhong, et al.
Publicado: (2021)

Multi-alleles predict primary non-response to infliximab therapy in Crohn’s disease
por: Zhang, Cai-Bin, et al.
Publicado: (2020)

Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease
por: Oh, Eun Hye, et al.
Publicado: (2017)

Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn’s disease under infliximab therapy
por: Cao, Wan-Ting, et al.
Publicado: (2022)

Maintenance treatment with infliximab for the management of Crohn’s disease in adults
por: Caviglia, Renato, et al.
Publicado: (2009)

Infliximab-induced intertriginous psoriasis in patient with Crohn's disease
por: Mola, Federica, et al.
Publicado: (2011)

Refractory Duodenal Crohn's Disease Successfully Treated with Infliximab
por: Kim, You Lim, et al.
Publicado: (2014)

Infliximab in the Treatment of Crohn Disease and Type 1 Diabetes
por: Timper, Katharina, et al.
Publicado: (2013)

Efficacy of Infliximab for the Treatment of Oral Manifestation of Crohn’s Disease
por: Aginbay, Aibar, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_24d3gdkdis0h6hc5bu5im9q42p